?> Open Orphan three upcoming scientific presentations - DirectorsTalk

Open Orphan three upcoming scientific presentations

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (LON:HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that three presentations discussing the data and learnings from recent clinical studies and projects will be presented at two upcoming conferences taking place in Belfast, Northern Ireland.

OPTIONS XI for the Control of Influenza is being held 26 – 29 September 2022 and hVIVO will be at booth 6 during the conference for potential partnering discussions. The 12th International RSV Symposium will take place on 29 September to 2 October 2022 and hVIVO will be at booth 6 during the conference for potential partnering discussions.

Details of the presentations at OPTIONS XI for the Control of Influenza are as follows:

Title:Immunomodulators and treatment of disease in the influenza human challenge model
Abstract:AOXI0665
Date:Wednesday, 28 September 2022
Location:Hall 1, Poster Board Number: P-532
Title:Influenza, COVID-19, RSV and HRV: translating efficacy testing of vaccine and drugs from human challenge models to the field
Abstract:AOXI0658
Date:Thursday, 29 September 2022 at 11:12 AM
Session:Oral Abstract Session: Translational: Influenza & COVID-19 – Human challenge models

Details of the presentation at the 12th International RSV Symposium are as follows:

Title:RSV vaccines/prophylactics: key learnings from the RSV challenge model and Efficacy of Vaccines
Abstract:ARNI0259
Date:Friday, September 30, 2022

The abstracts and posters will be available on hVIVO’s website from 4 October 2022 here.  

Open Orphan plc is changing its name to hVIVO plc (AIM and Euronext: HVO), which is expected to take effect on the AIM market of the London Stock Exchange and the Euronext Growth Exchange market on 26 October 2022.

hVIVO is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan name change to hVIVO effective 26th October 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to its announcement on 8 September 2022,

Open Orphan Plc

Open Orphan to hold a Capital Markets Day on 2 November 2022

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has

Open Orphan Plc

Open Orphan appoints Stephen Pinkerton as CFO

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (Ticker: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical

Open Orphan Plc

Celebrating 25th Anniversary in DE STAL in Leiden

Venn Life Sciences would like to invite you to celebrate their 25th anniversary in DE STAL in Leiden on October 18th. We are delighted to present our team members who will give a short talks on biologics

Open Orphan Plc

Why it’s important to stay hydrated when you have asthma

During the last 10 years, it has been proven that there could be a connection and repercussion between hydration and different respiratory diseases. Dehydration is a common symptom of allergies but an unusual trigger for asthma.

Open Orphan Plc

Open Orphan further positive data for FLU-v

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical

Open Orphan Plc

Open Orphan reiterates £50m profit guidance

Dublin and London-listed pharmaceutical company Open Orphan announced on Thursday that it will rename itself Hvivo from next month. The rare and orphan drug consulting services platform also reported results for the first half of the

Open Orphan Plc

Open Orphan rebrands to Hvivo

Open Orphan is changing its name as CEO Yamin Khan said the company achieved its ‘key goal’ of double-digit earnings for the first time. Dublin-based pharma services company Open Orphan announced today (8 September) that it

Open Orphan Plc

Open Orphan to change name to hVIVO plc

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its intention to change its name to hVIVO

Open Orphan Plc

Open Orphan continued its profitable momentum into 2022

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (LON:HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human

Open Orphan Plc

Open Orphan’s hVIVO awarded CAP accreditation

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that its clinical laboratories in Queen Mary’s Bioenterprise Centre

Open Orphan Plc

Clinical trial management

Added value for working with Venn Medical Writing group » End-to-end support: Venn clinical trial management group has the expertise to set-up, coordinate and deliver clinical trials including vendor selection, investigational product logistics, data management, safety

Open Orphan Plc

Open Orphan to release its interim results on 8 September 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for

Open Orphan Plc

Venn Life Sciences: Medical writing

Team experience Small dedicated team of Senior Medical Writers and Clinical Trial Assistant with total team experience in clinical and regulatory writing of more than 75 years In addition, Venn is working with a flexible shell